| A031203 | RANDOMIZED PHASE II STUDY COMPARING CABOZANTINIB (NSC #761968 AND IND #116059) WITH COMMERCIALLY SUPPLIED SUNITINIB IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA | Open (affiliates only) |
| ADVL1622 | Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors | Open |
| AMC-095 | A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma | Open |
| APEC1621SC | NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) | Open |
| AREN03B2 | Renal Tumors Classification, Biology, and Banking Study | Open |
| BTCRC-GI13-002 | An Open Label Randomized Phase I/II Trial of TAK-228 Compared to Sorafenib in Patients with Advanced or Metastatic Hepatocellular Carcinoma | Open |
| DFCI17-064/OMNIVORE | Phase II study of Optimized Management of NIVOlumab based on REsponse in patients with advanced renal cell carcinoma (OMNIVORE study) | Open |
| GO30140 | An Open-Label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (ANTI-PD L1 Antibody) Administered in combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors. | Open |
| INCAGN1876-201 | A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination with Immune therapies in Subjects with Advanced or Metastatic Malignancies | Open |
| LCCC1529 | New Approaches to Identifying Malignancy in Cystic Kidney Lesions in Patients with Chronic Kidney Disease | Open (affiliates only) |
| LCCC1623 | Interviewing cancer patients and caregivers about using symptom questionnaires to improve quality of cancer care | Open |
| LCCC1723 | Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients with CKD extension (CEUS CKDx) | Open |
| LCCC1734 | Adaptation of the Parenting Concerns Questionnaire for Patients with Illness | Open |
| LCCC1802 | Randomized Trial of Parotid Sparing Whole Brain Radiation | Open |
| MCC-16962 | A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid Tumors | Open |
| MDT16075 | OsteoCool Tumor Ablation Post-Market Study (OPuS One) | Open |
| ML28897PRO/02 | My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents. | Open |
| NC-6300-001 | A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma | Open |
| PCRC-14-07 | Caregiver-‐guided pain management training in palliative care | Open |
| WO39210 | A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti−PD-L1 Antibody) As Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy | Open |